News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sagent Pharmaceuticals, Inc. Raises $40 Million in Two Tranches of a Series B Financing



4/8/2010 11:18:30 AM

SCHAUMBURG, Ill., April 8 /PRNewswire/ -- Sagent Pharmaceuticals, a privately held specialty pharmaceutical company, announced today that it has raised $40 million through two tranches of a strategic Series B financing. In this round, a $10 million investment was made by Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun), and the remaining $30 million was contributed by an unnamed China-focused private equity investment fund. To date, including this financing, Sagent has raised $153 million in equity capital.

About Sagent Pharmaceuticals

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit www.SagentPharma.com.

CONTACT: Investors, Ronald Pauli of Sagent Pharmaceuticals,
+1-847-908-1604; or Media, Aline Schimmel of WCG, +1-312-646-6295, for
Sagent Pharmaceuticals

Web site: http://www.SagentPharma.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES